Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 1:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Brain and Central Nervous System Tumors
Interventions
gefitinib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more
Conditions
Brain and Central Nervous System Tumors
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 39 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Cerebral Anaplastic Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood Infratentorial Ependymoma, Childhood Oligodendroglioma, Childhood Spinal Cord Neoplasm, Childhood Supratentorial Ependymoma, Recurrent Childhood Brain Neoplasm, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway Glioma
Interventions
Cediranib Maleate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
11
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Conditions
Brain and Central Nervous System Tumors
Interventions
Not listed
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Boston, Massachusetts + 5 more
Conditions
Cancer
Interventions
entinostat
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Bethesda, Maryland
Conditions
Posterior Fossa Ependymoma (PFEPN)
Interventions
Trastuzumab after SubQ GM-CSF, Trastuzumab in combination with SubQ GM-CSF
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Months to 21 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Brain and Central Nervous System Tumors, Radiation Toxicity
Interventions
EGb761, donepezil hydrochloride, cognitive assessment
Dietary Supplement · Drug · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
4
States / cities
Phoenix, Arizona • Rome, Georgia • Winston-Salem, North Carolina + 1 more
Conditions
Brain and Central Nervous System Tumors, Neuroblastoma
Interventions
filgrastim, carboplatin, cyclophosphamide, thiotepa, vincristine sulfate, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 21 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
13
States / cities
Los Angeles, California • Orange, California • Denver, Colorado + 8 more
Conditions
Brain Tumor Recurrent
Interventions
Methotrexate, Etoposide, Ommaya Reservoir
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Year to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Houston, Texas
Conditions
Brain Tumor Recurrent
Interventions
5-Azacytidine
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Year to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Houston, Texas
Conditions
Central Nervous System Neoplasms, Medulloblastoma
Interventions
Pomalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
1 Year to 21 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
6
States / cities
Stanford, California • Gainesville, Florida • Chicago, Illinois + 3 more
Conditions
Ependymomas, Gliomas, PNET, Pineal Tumors, PCNSL (Primary CNS Lymphoma)
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Long-term Effects Secondary to Cancer Therapy in Children
Interventions
filgrastim, acetylcysteine, carboplatin, cyclophosphamide, etoposide phosphate, mannitol, sodium thiosulfate
Biological · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
1 Year to 18 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Recurrent Childhood Medulloblastoma, Recurrent Ependymoma, Recurrent Medulloblastoma
Interventions
Laboratory Biomarker Analysis, Natural Killer Cell Therapy
Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 1 Interventional Results available

HUMC 1612: Optune NovoTTF-200A System

NCT03128047
Conditions
High Grade Glioma, Ependymoma
Interventions
Optune NovoTTF-200A System
Device
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
5 Years to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Orlando, Florida • Hackensack, New Jersey
Conditions
Recurrent Childhood Medulloblastoma, Recurrent Childhood Ependymoma, Childhood Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumor With Abundant Neuropil and True Rosettes, Metastatic Malignant Neoplasm to the Leptomeninges
Interventions
Intra thecal methotrexate, topotecan, cyclophosphamide
Drug
Lead sponsor
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Other
Eligibility
Up to 22 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Miami, Florida
Conditions
Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride, temozolomide, vincristine sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
16
States / cities
Birmingham, Alabama • Orange, California • Stanford, California + 13 more
Conditions
Ependymoma, Ewing Sarcoma, High-grade Glioma, Leukemia and Lymphoma, Medulloblastoma, Miscellaneous Brain Tumors, Miscellaneous Solid Tumors, Neuroblastoma, Relapsed, Refractory Malignant Neoplasms, Rhabdomyosarcoma
Interventions
Nivolumab, NKTR-214
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Up to 30 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Little Rock, Arkansas • St Louis, Missouri
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide, protein expression analysis, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis, immunoenzyme technique
Drug · Genetic · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Conditions
Neoplasms, Brain, Glioblastoma Multiforme, Glioblastoma of Cerebellum, Neoplasms, Astrocytoma, Astrocytoma, Cerebellar, Neuroectodermal Tumors, Neuroectodermal Tumors, Primitive, Cerebellar PNET, Childhood, Cerebellar Neoplasms, Cerebellar Neoplasms, Primary, Cerebellar Neoplasm, Malignant, Cerebellar Neoplasm Malignant Primary, Neoplasm Metastases, Neoplasm Malignant, Neoplasms, Neuroepithelial, Neoplasms, Germ Cell and Embryonal, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Central Nervous System Neoplasms, Primary, Central Nervous System Neoplasms, Malignant, Nervous System Neoplasms, Neoplasms by Site, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Medulloblastoma Recurrent, HSV, Virus, Pediatric Brain Tumor, Nervous System Cancer, Primitive Neuroectodermal Tumor (PNET) of Cerebellum
Interventions
G207
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
3 Years to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
3
States / cities
Birmingham, Alabama • St Louis, Missouri • Houston, Texas
Conditions
Brain and Central Nervous System Tumors
Interventions
phenylacetate
Drug
Lead sponsor
Texas Children's Cancer Center
Other
Eligibility
2 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 3 more
Conditions
Brain Tumor, Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Brain Stem Glioma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Mixed Glioma
Interventions
ritonavir, lopinavir
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Brain Tumors, Central Nervous System Tumors, Neuroblastoma, Sarcoma
Interventions
filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, thiotepa, vincristine sulfate, conventional surgery, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 2 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2011
U.S. locations
66
States / cities
Duarte, California • Los Angeles, California • Madera, California + 52 more
Conditions
Brain and Central Nervous System Tumors, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
calcitriol, carboplatin
Dietary Supplement · Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania